C. Difficile

Today, we celebrate the crucial role of infectious disease pharmacists in combating infectious diseases and promoting patient safety.

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.

New findings from clinical trials reveal that Rebyota, a rectally administered treatment, demonstrates improved outcomes in patients with recurrent Clostridioides difficile infection (rCDI).

The presence of certain bacteria in the gastrointestinal tract may limit the effectiveness of antibiotic treatment for Clostridioides difficile.

A study of patients with recurrent Clostridioides difficile infection (rCDI) found that Rebyota, a rectally administered live biotherapeutic, was considered easy, quick, and appealing due to the lack of bowel preparation.

This study found a high proportion of reduced vancomycin susceptibility in C difficile patients, leading to lower rates of sustained clinical response.

From the relationship between nutrition and the gut to a newly approved C difficile therapeutic, these are the must-read stories in gastro health.

Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.

Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.

A new study showed an introduction of beneficial microbiota.

Antifungal therapy was frequently initiated before essential diagnostic elements confirmed invasive fungal infections in critically ill COVID-19 patients.

Ferring’s Rebyota therapeutic was studied in this population and demonstrated a 79% efficacy.

Investigators in Canada found no evidence to support extending treatment for Clostridioides difficile infection for patients on concurrent antibiotics

Ferring’s Rebyota, which was FDA approved late last year, demonstrated a high efficacy and favorable safety profile in the prevention of recurrent Clostridioides difficile.

Joseph Reilly, BS, PharmD, BCGP; Candace Cotto, RN; and Andrew Skinner, MD, review C. difficile infection (CDI), its risk factors, symptoms, and quality of life for the patient.

Experts provide an overview of the gut microbiome and its importance to nutrition and overall health.

A novel oral microbial therapy under development by Vedanta Biosciences reduced the risk of recurrence of Clostridioides difficile infection in a phase 2 clinical trial.

The findings of this study could pave the way for new, disease-targeted probiotics.

Data from New Haven County, Connecticut, suggests the pandemic might have hurt efforts to curb recurrent CDI.

This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.

The floods, heat waves, droughts, and other calamities caused by excessive greenhouse gas emissions also make us more vulnerable to ill effects of pathogens such as bacteria, viruses, plants and fungi.

The Peggy Lillis Foundation will host its summit on Monday and has a number of speakers who will discuss topics related to this healthcare-associated infection (HAI).

While efforts to curb in-hospital infection seem to have paid off, community-acquired cases appear headed in the opposite direction.

Catch up with this week's 5 most-read infectious disease stories.

Reducing unnecessary antibiotic prescriptions for viral upper respiratory tract infections is crucial to stop the spread of antimicrobial resistance.

2 CDI recurrences occurred in this study, both in placebo recipients who were immunocompromised.

This study implemented an Electronic Health Record in a major hospital system to catch otherwise undetected C diff infections.